论文部分内容阅读
目的 观察通过两种不同途径制备的中药复方“肝纤方”含药血清对大鼠肝星状细胞(HSC)在各个水平上的作用 ,以明确其抗肝纤维化的分子学机制和研究有关中药抗肝纤维化的血清药理学实验方法。方法 采用血清药理学方法制备两种含药血清 门静脉血清和外周静脉 (体静脉 )血清 ,作用于离体培养的大鼠传 2代HSC ,以氚标胸腺嘧啶 ([3 H]TdR)和氚标脯氨酸 ([3 H ]Pro)核素掺入试验、流式细胞仪、逆转录 聚合酶链反应 (RT PCR)等方法检测HSC增殖及其胶原合成量、细胞增殖周期、Ⅰ型前胶原mRNA表达水平等指标。结果 门静脉血清组 [3 H ]TdR和 [3 H]Pro的掺入量分别为 (5 69.2± 19.8)cpm/孔和(90 7.3± 10 .3 )cpm /孔 ,与对照组相比均减少(P <0 .0 5 ) ,外周静脉血清组的为 (5 92 .8± 10 .9)cpm/孔和 10 2 5 .2± 5 4.0cpm/孔 ,与对照组相比前者减少 (P <0 .0 5 )而后者差异无显著性 ;门静脉含药血清提高HSC的G0 /G1期的比例和降低G2 /M及S期的比例 (P <0 .0 5 ) ,而外周静脉血清对各细胞周期无影响 (P >0 .0 5 ) ;I型前胶原mRNA的PC mRNA/GAPDH mRNA比值为门静脉血清组 0 .42± 0 .0 9和外周静脉血清组 0 .72± 0 .0 5 ,与对照组相比均降低 ,而门静脉血清组则更低 (P <0 .0 5 )。结论 肝纤方抗肝纤维化的?
Objective To observe the effect of serum containing the liver-fibrin formula “Heganxianfang” prepared by two different ways on rat hepatic stellate cells (HSCs) at various levels to clarify the molecular mechanism and research related to anti-hepatic fibrosis Serum pharmacological experimental method for anti-hepatic fibrosis of traditional Chinese medicine. METHODS Serum pharmacological methods were used to prepare two kinds of drug-containing serum portal vein serum and peripheral vein (body vein) serum for the passage of HSCs in vitro in vitro, using thymidine ([3H]TdR) and sputum. Radiolabeled proline ([3 H ]Pro) nuclide incorporation assay, flow cytometry, and reverse transcription polymerase chain reaction (RT PCR) were used to detect HSC proliferation and collagen synthesis, cell proliferation cycle, and type I Collagen mRNA expression levels and other indicators. Results The incorporation of [3 H ]TdR and [3 H]Pro in portal vein sera was (5 69.2 ± 19.8) cpm/well and (90 7.3 ± 10 .3) cpm/well, respectively, and decreased compared with the control group. (P <0.05), (5 92.8 ± 10.9) cpm/well in the peripheral vein sera group and 10 2 5 .2 ± 5 4.0 cpm/well in the peripheral vein sera, and the former decreased compared with the control group (P < 0.05). <0. 0 5) while the latter difference was not significant; portal vein drug-containing serum increased the ratio of G0/G1 phase of HSC and decreased the ratio of G2 / M and S phase (P <0.05), while peripheral vein serum There was no effect on cell cycle (P > 0.05); the PC mRNA/GAPDH mRNA ratio of type I procollagen mRNA was 0.42 ± 0.09 in the portal vein serum group and 0.72 ± 0.0 in the peripheral vein serum group. 5, compared with the control group, decreased, while the portal vein serum group was lower (P <0.05). Conclusion liver fibrosis anti-liver fibrosis?